Member Info for Noise

Drac, I checked that statement, he actually said something like talks are complicated as there are six parties involved (I interpreted this as Valirx, Valiseek, Tangent Reprofiling Ltd, +2-3 pharmas showing a potential interest).

Personally, I thought the fact he referenced geographical territory boundaries being an ongoing debate as a specific sign that there were negotiations ongoing. It would be a rather odd and fabricated comment otherwise. I am inclined to consider that after 14 months and repeated RNS notifications that talks are/were in progress.

As for the diehard anti-Valirx types, it's hard to assume their raison d'être. The government seems to endorse Valirx, either because the model is cheaper than the traditional biotech model (spend a billion, BoD become obscenely rich, bill the NHS!), or because they liked the drugs in development. So the obvious candidates would be established companies seeking to protect multi-billion $ revenue streams, asset strippers trying to bankrupt the company and recover the assets (there are 1-2 obvious candidates), plus some UK biotechs who seem to be fighting for grant money/commercial partnerships (in Scancell's case, I have to note they have been fighting to get grant money from CR UK, who coincidentally sold the VAL201 commercial rights to Valirx, do Scancell see as us competition? who knows). There will be a mix of genuine investors who will, no doubt, be quite horrified at their share performance (I personally fell out with Satu over this a long time ago). Alternatively, they wake up every day and hate Valirx so much they post all day, evening and weekends on a variety of usernames created specifically for the sole purpose of spamming the board....

Still....I am curiously rather fond of this company. I cannot predict the future, I assume a mix of death, taxes and equity raising, with potential niche cancer drugs developed along the way.

On the positive side, on Monday it will be exactly 3 months since the last VAL201 clinical update (I'm not counting the statistics update).

Who knows?

Obelix,

This is a clinical trial database, there is no option to mark a trial as 'successful' - you can have a variety of status, including: Not yet recruiting, recruiting, active, suspended, terminated, unknown, or completed.

I think I'd prefer to be labelled completed out of that selection!

Almost certain the phase 3 has not been submitted, it would probably be easier if the corporate situation was announced before that was formally submitted.

https://clinicaltrials.gov/ you'd find it here by looking for VAL401 or possibly risperidone.

Yes I guess it's a waiting game on 401 now

Similar for 201/301, at least we have some info on those from page 42 of https://media.moneyam.com/a/2018/11/1-ValiRx-Dr.-George-Morris.pdf

Obelix, it also appears to suggest all the pre-clinical VAL301 work is complete and Phase 1 is starting?

Frankly, I think they would file me as a "blathering idiot" and politely ignore me. I might get more luck petitioning Google

Based on what Syncona have shown an interest in so far, VAL101/GeneICE might be more interesting for them in their core gene therapy markets. Although having Axumin (metastatic prostate imaging tool) and VAL201 in the same company does have a nice marketing alignment to it.

Syncona are but one of many large biotechs out there looking for drugs - if/when one of them decides to make the leap it'll be interesting to watch. Starting to lose my patience here a bit...

Oh well, at least my funds, FTSE stocks and Syncona shares are doing well recently.

Syncona new corporation presentation out today - a very interesting company that one. Attempts to be doing what Valirx are trying to do, albeit with a few billion £ in capital to start with. Some useful prostate imaging treatments too (I don't think they have any prostate CAR-T therapies yet).

You assume he is directly responsible for finance? From recollection his title is Chief Operations Officer and primarily a technical/project manager type role. Although I suppose he is the public face of VAL.

I would have assumed that the CEO (Satu), Chairman (Gerry) and CFO would have more direct input into finance. Morris would probably have a far easier life if he didn't have to deal with equity raisings and associated aggro....I'm sure I would!

Calm down, you're offended at George because someone he doesn't communicate with referred to Valirx as "his company"?

At least the "second hand shareholders" crowd mis-quote him from a 3 year old e-mail comparing equity investors and trades completed on the open market.

Blue Earth is making ~ £44mpa profit with sales revenue growing at ~15% per quarter. Give that steady global rollout another 12-18 months and BED will require a significant valuation uplift.

Wonder who the two new companies due to be added to the portfolio are?

Ladies and gentlemen,

When someone sells shares on the market, they sell them to a buyer.

When someone buys .. they buy from a seller.

Now please stop talking about trades being a buy or a sell.

There's still news around.

I think the quarterly news update is scheduled for tomorrow (13th Feb).

Blah I'd love this UCLH research paper to be updated with a 3 year follow up

https://www.researchgate.net/publication/313327620_A_first-in-human_FIH_phase_III_dose_escalation_pharmacokinetic_PK_study_to_assess_the_safety_and_tolerability_of_VAL-201_in_patients_with_advanced_prostate_cancer_APC_and_other_advanced_solid_tumours

At that point 7 patients were evaluable at low doses, UCLH still managed to report:

"Early signs of clinical activity have been observed with prolonged PSA doubling time (n = 2), stabilisation of PSA (n = 1) and >50% decrease in PSA (n = 1,Table)"

Yes they have had 13 months now, that's roughly how long I'd expect negotiations to take.

Isleworth, it may be conjecture, but in my experience on AIM, I am inclined to believe that most significantly large orders reported on the market at around 4:30pm are often related to brokers buying equity chunks to sell onto the market.

I base that on rarely seeing a holdings RNS in the following days, together with it being a common theme during periods when AIM companies are selling equity onto the market.

You could imagine it, boss tells you to dripfeed £40k onto the market slowly over the day, when finished hand it over to the inhouse compliance team at the end of the day for compliance reporting.

My opinion could be, and often is, garbage :)

I still figure the best solution (and possibly the long term intention of several resident sockpuppets) would be to reverse Valirx into some kind of FTSE company or institutional bioscience fund. Interesting to watch, I think this is the year that the Valirx red/black coin flip gets determined...fingers crossed but a rational pessimistic mind is recommended.

Yes one of my friends has severe endo, apparently the options are androgen blockers (hmmmmm) or unpleasant surgergy to cut them out.

I'm wondering if it might be trend investors

https://www.england.nhs.uk/publication/universal-personalised-care-implementing-the-comprehensive-model/

My only thought is that VAL401 trial details are generally published now, indicating partnering imminent (or...not) and whether Satu's vague RNS earlier this week about the NHS Long Term Plan...actually had some substance that she couldn't specifically point out.

There has been quite a lot of discussion about this 10 year plan over the last month or so, so perhaps there's some political edge to this jump.